ArticleEuropean journal of medical research2025
Association between the serum uric acid-to-high-density lipoprotein cholesterol ratio and microalbuminuria in individuals with type 2 diabetes mellitus.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association Between Time-Averaged Serum Uric Acid and Renal Outcomes in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Multicenter Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Cross-sectional association of the uric acid-to-HDL cholesterol ratio with diabetic kidney disease in patients with type 2 diabetes.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to examine the association between the serum uric acid-to-high-density lipoprotein cholesterol ratio (UHR) and the presence of microalbuminuria in individuals diagnosed with type 2 diabetes mellitus (T2DM), and to evaluate the potential of UHR as a predictive marker for early diabetic nephropathy (DN).
methodsA cross-sectional study was conducted at The First Hospital of Longyan City between 2022 and 2024, which included 563 individuals with T2DM (38.54% male, 61.46% female). The exposure variable was UHR, while the outcome variable was microalbuminuria, defined as a urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g and < 300 mg/g. Covariates included age, sex, diabetes duration, blood pressure parameters, waist-to-height ratio, glycated hemoglobin (HbA1c), triglyceride-glucose body mass index (TyG-BMI index), and medication history. Multivariate logistic regression analysis was applied to evaluate the association between UHR and microalbuminuria. A generalized additive model (GAM) was employed to assess potential nonlinear associations. Receiver-operating characteristic (ROC) curves were generated to assess predictive performance.
resultsFollowing full adjustment for covariates, UHR demonstrated a significant association with microalbuminuria (odds ratio [OR] = 2.06, 95% confidence interval [CI]: 1.03-4.12, p = 0.041). GAM analysis revealed a positive linear association between UHR and the risk of microalbuminuria. In the sex-specific predictive model, the area under the curve (AUC) was 0.738 (95% CI 0.642-0.819) for female patients and 0.705 (95% CI 0.630-0.765) for male patients.
conclusionUHR was identified as an independent risk factor for microalbuminuria in individuals with T2DM, demonstrating a dose-response relationship. Incorporating UHR into sex-specific predictive models improved the accuracy of microalbuminuria risk assessment, supporting its potential utility in the early identification and prevention of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.